|
"coumar ms"的相關文件
顯示項目 46-70 / 71 (共3頁)
<< < 1 2 3 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2011-04-28 |
Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-Fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents
|
Tung, YS;Coumar, MS;Wu, YS;Shiao, HY;Chang, JY;Liou, JP;Shukla, P;Chang, CW;Chang, CY;Kuo, CC;Yeh, TK;Lin, CY;Wu, JS;Wu, SY;Liao, CC;Hsieh, HP |
| 國家衛生研究院 |
2010-12 |
Discovery of non-glycoside sodium-dependent glucose Co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening
|
Wu, JS;Peng, YH;Wu, JM;Hsieh, CJ;Wu, SH;Coumar, MS;Song, JS;Lee, JC;Tsai, CH;Chen, CT;Liu, YW;Chao, YS;Wu, SY |
| 國家衛生研究院 |
2010-10-28 |
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and michael acceptor group for maximal potency
|
Wu, CH;Coumar, MS;Chu, CY;Lin, WH;Chen, YR;Chen, CT;Shiao, HY;Rafi, S;Wang, SY;Hsu, H;Chen, CH;Chang, CY;Chang, TY;Lien, TW;Fang, MY;Yeh, KC;Chen, CP;Yeh, TK;Hsieh, SH;Hsu, JT;Liao, CC;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2010-10 |
Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists
|
Peng, YH;Coumar, MS;Leou, JS;Wu, JS;Shiao, HY;Lin, CH;Lin, WH;Lien, TW;Chen, X;Hsu, JT;Chao, YS;Huang, CF;Lyu, PC;Hsieh, HP;Wu, SY |
| 國家衛生研究院 |
2010-08 |
Lead optimization of furanopyrimidine Aurora kinase inhibitors: Development of in vivo active agents in tumor xenograft models
|
Hsieh, HP;Chu, CY;Coumar, MS;Lin, WH;Chen, CT;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2010-06-15 |
Fast-forwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification
|
Coumar, MS;Chu, CY;Lin, CW;Shiao, HY;Ho, YL;Reddy, R;Lin, WH;Chen, CH;Peng, YH;Leou, JS;Lien, TW;Huang, CT;Fang, MY;Wu, SH;Wu, JS;Chittimalla, SK;Song, JS;Hsu, JT;Wu, SY;Liao, CC;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2010-02-25 |
Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives
|
Yeh, JY;Coumar, MS;Horng, JT;Shiao, HY;Kuo, FM;Lee, HL;Chen, IC;Chang, CW;Tang, WF;Tseng, SN;Chen, CJ;Shih, SR;Hsu, JT;Liao, CC;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2010-02-01 |
Identification, SAR studies, and X-ray Co-crystallographic analysis of a novel furanopyrimidine aurora kinase a inhibitor
|
Coumar, MS;Tsai, MT;Chu, CY;Uang, BJ;Lin, WH;Chang, CY;Chang, TY;Leou, JS;Teng, CH;Wu, JS;Fang, MY;Chen, CH;Hsu, JTA;Wu, SY;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2009-08-13 |
Synthesis and evaluation of 3-aroylindoles as anticancer agents: Metabolite approach
|
Wu, YS;Coumar, MS;Chang, JY;Sun, HY;Kuo, FM;Kuo, CC;Chen, YJ;Chang, CY;Hsiao, CL;Liou, JP;Chen, CP;Yao, HT;Chiang, YK;Tan, UK;Chen, CT;Chu, CY;Wu, SY;Yeh, TK;Lin, CY;Hsieh, HP |
| 中國醫藥大學 |
2009-08 |
Synthesis and Evaluation of 3-Aroylindoles as Anticancer Agents: Metabolite Approach.
|
(Wu YS); (Coumar MS); (Chang JY); (Sun HY); (Kuo FM); (Kuo CC); (Chen YJ); (Chang CY); (Hsiao CL); (Liou JP); (Chen CP); 姚賢宗(Hsien-Tsung Yao); (Chiang YK); (Tan UK); (Chen CT); (Chu CY); (Wu SY); (Yeh TK); (Lin CY); (Hsieh HP)* |
| 國家衛生研究院 |
2009-07-23 |
Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity
|
Chiang, YK;Kuo, CC;Wu, YS;Chen, CT;Coumar, MS;Wu, JS;Hsieh, HP;Chang, CY;Jseng, HY;Wu, MH;Leou, JS;Song, JS;Chang, JY;Lyu, PC;Chao, YS;Wu, SY |
| 國家衛生研究院 |
2009-07-03 |
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers
|
Cheung, CH;Chen, HH;Kuo, CC;Chang, CY;Coumar, MS;Hsieh, HP;Chang, JY |
| 國家衛生研究院 |
2009-04-23 |
Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists
|
Lin, CH;Peng, YH;Coumar, MS;Chittimalla, SK;Liao, CC;Lyn, PC;Huang, CC;Lien, TW;Lin, WH;Hsu, JT;Cheng, JH;Chen, X;Wu, JS;Chao, YS;Lee, HJ;Juo, CG;Wu, SY;Hsieh, HP |
| 國家衛生研究院 |
2009-04 |
Aurora kinase inhibitors in preclinical and clinical testing
|
Cheung, CH;Coumar, MS;Hsieh, HP;Chang, JY |
| 國家衛生研究院 |
2009-03 |
Advances in Aurora kinase inhibitor patents
|
Coumar, MS;Cheung, CHA;Chang, JY;Hsieh, HP |
| 國家衛生研究院 |
2009-03 |
Discovery and development of novel furano-pyrimidine analogs as Aurora kinase inhibitors
|
Hsieh, HP;Coumar, MS;Lin, CW;Reddy, GR;Tsai, MT;Lin, WH;Hsu, TA;Wu, SY |
| 國家衛生研究院 |
2009-02-26 |
Structure-based drug design of novel aurora kinase a inhibitors: Structural basis for potency and specificity
|
Coumar, MS;Leou, JS;Shukla, P;Wu, JS;Dixit, AK;Lin, WH;Chang, CY;Lien, TW;Tan, UK;Chen, CH;Hsu, JTA;Chao, YS;Wu, SY;Hsieh, HP |
| 國家衛生研究院 |
2008-12-25 |
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents
|
Reddy, GR;Kuo, CC;Tan, UK;Coumar, MS;Chang, CY;Chiang, YK;Lai, MJ;Yeh, JY;Wu, SY;Chang, JY;Liou, JP;Hsieh, HP |
| 國家衛生研究院 |
2008-06 |
Synthesis, beta-adrenergic receptor binding and antihypertensive potential of vanillin-derived phenoxypropanolamines
|
Coumar, MS; Jindal, DP; Bruni, G; Massarelli, P; Singh, R; Sharma, AK; Nandakumar, K; Bodhankar, SL |
| 國家衛生研究院 |
2008-03-01 |
Aurora kinase A inhibitors: Identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold
|
Coumar, MS; Wu, JS; Leou, JS; Tan, UK; Chang, CY; Chang, TY; Lin, WH; Hsu, JTA; Chao, YS; Wu, SY; Hsieh, HP |
| 臺北醫學大學 |
2008 |
Synthesis and Structure-Activity Relationships of 2-Amino and 2-Hydroxy-1-Aroylnaphthalenes as Potent Antitubulin Agents
|
劉景平; Reddy GR; Kuo CC; Tan UK; Coumar MS; Chang CY; Lai MJ; Wu SY; Chang JY; Liou JP; Hsieh HP |
| 國家衛生研究院 |
2007-03-01 |
3-[2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes
|
Coumar, MS; Chang, CN; Chen, CT; Chen, X; Chien, CH; Tsai, TY; Cheng, JH; Wu, HY; Han, CH; Wu, SH; Huang, YW; Hsu, T; Hsu, LJ; Chao, YS; Hsieh, HP; Jiaang, WT |
| 國家衛生研究院 |
2006-09 |
MEDI 416-3- 2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino -3-methyl-butyr amide analogs as DPP-IV inhibitors for the treatment of type-II diabetes
|
Hsieh, HP;Coumar, MS;Chang, CN;Wu, SH;Chen, X;Chen, CT;Jiaang, WT |
| 國家衛生研究院 |
2006-06-15 |
Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors
|
Tsai, TY; Coumar, MS; Hsu, T; Hsieh, HP; Chien, CH; Chen, CT; Chang, CN; Lo, YK; Wu, SH; Huang, CY; Huang, YW; Wang, MH; Wu, HY; Lee, HJ; Chen, X; Chao, YS; Jiaang, WT |
| 國家衛生研究院 |
2006-01-12 |
2-[3-[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]-1,2,3,4-tetrahydroisoquinoline: A potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV
|
Tsu, H; Chen, X; Chen, CT; Lee, SJ; Chang, CN; Kao, KH; Coumar, MS; Yeh, YT; Chien, CH; Wang, HS; Lin, KT; Chang, YY; Wu, SH; Chen, YS; Lu, IL; Wu, SY; Tsai, TY; Chen, WC; Hsieh, HP; Chao, YS; Jiaang, WT |
顯示項目 46-70 / 71 (共3頁)
<< < 1 2 3 > >>
每頁顯示[10|25|50]項目
|
